Literature DB >> 25901728

Use of the QuantiFERON®-TB Gold in Tube test for screening TB contacts and predictive value for active TB.

Takashi Yoshiyama1, Nobuyuki Harada, Kazue Higuchi, Masami Saitou, Seiya Kato.   

Abstract

BACKGROUND: This study estimated the incidence of progression to active tuberculosis (TB) among contacts categorized by QuantiFERON(®)-TB Gold in Tube (QFT-GIT) test results and investigated other risk factors related to progression to TB.
METHODS: Contacts of patients with TB were tested using QFT-GIT and were followed up every 6 months at public health centers to detect clinical progression to TB.
RESULTS: Analysis of a retrospective cohort revealed that, of the 625 contacts, 168 were QFT-GIT positive and 457 were negative. Of these, 10 (6%) QFT-GIT-positive and two (0.4%) QFT-GIT-negative contacts progressed to TB during the follow-up period (p < 0.01, statistically significant). Multivariable logistic regression analysis revealed that QFT-GIT positivity (p < 0.01), contact of index patients with many other positive contacts (p < 0.01), household contact (p = 0.014), and untreated latent TB infection (p = 0.047) were independent risk factors for progression to TB during an average follow-up period of 637 days.
CONCLUSIONS: Progression to TB among QFT-GIT-positive contacts was higher than among QFT-GIT-negative contacts. Other independent risk factors for progression to TB were index cases with more QFT-GIT-positive contacts as well as household contacts.

Entities:  

Keywords:  QFT-GIT; Tuberculosis; diseases; infection; interferon-gamma release test

Mesh:

Year:  2015        PMID: 25901728     DOI: 10.3109/23744235.2015.1026935

Source DB:  PubMed          Journal:  Infect Dis (Lond)        ISSN: 2374-4243


  1 in total

1.  Overweight, Obesity, and Older Age Favor Latent Tuberculosis Infection among Household Contacts in Low Tuberculosis-Incidence Settings within Panama.

Authors:  Idalina Cubilla-Batista; Nadia Ruiz; Dilcia Sambrano; Juan Castillo; Markela O de Quinzada; Begoña Gasteluiturri; Amador Goodridge
Journal:  Am J Trop Med Hyg       Date:  2019-05       Impact factor: 2.345

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.